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patients receiving parenteral nutrition (PN) administered via a pre-
mixed multichamber bag (MCB) or compounded solutions (COM).
Design: A retrospective database analysis of critically ill patients
(intensive care unit stay Z 3 days) receiving PN and discharged
between January 1, 2010, and June 30, 2011, using the Premier Hospital
Database. Patients were identiﬁed as receiving MCB or COM on the
basis of product description codes. Primary outcomes were length of
stay (LOS) and total costs. Comorbidities and clinical outcomes were
identiﬁed using International Classiﬁcaion of Diseases, Ninth Revision
diagnosis codes. All costs reported were for inpatient services only.
Patients receiving MCB and COM were matched on key patient and
hospital characteristics using a propensity score methodology. Multi-
variate regression models for cost and LOS used generalized linear
models with a log link and gamma distribution. Results: A total of
42,631 patients met the inclusion criteria (MCB ¼ 5,679; COM ¼ 36,952),nternational Society for Pharmacoeconomics and
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Open access under CC BY-NC-ND license.and the ﬁnal matched population included 3,559 patients from each
cohort. Baseline patient and hospital characteristics were well
matched between groups. Adjusted multivariate models demonstrated
a small difference between groups for LOS (MCB ¼ 9.40 days vs. COM ¼
9.65 days; P ¼ 0.014). In addition, patients receiving MCB incurred
approximately 9.1% less in total costs (MCB ¼ $37,790 vs. COM ¼
$41,569; P o 0.001). Conclusions: Overall, patients receiving MCB and
COM experienced similar LOS, though patients receiving MCB had
signiﬁcantly lower overall costs. Interpretation of the study ﬁndings is
subject to several limitations, and additional studies that include
explicit identiﬁcation of the method for compounding are needed.
Keywords: hospital compounded bag, infection, multichamber bag,
parenteral nutrition, ready-to-use, total cost.
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Parenteral nutrition (PN) has been established as the standard of
care for critically ill patients with dysfunctional gastrointestinal
tracts since the 1960s [1–3]. Although PN is a common treatment
in this population, there is uncertainty regarding optimal clinical
practices for its use. PN may be administered through various
techniques, which include premixed multichamber formulations
and compounded formulations.
During the PN compounding process, there is an associated
4.4% to 6.7% contamination rate [4,5]. Techniques leading to
fewer manipulations of infusion containers, sets, syringes, nee-
dles, and so forth, thereby minimizing the potential for contam-
ination during PN preparation and administration, are highly
favored. Premixed and ready-to-use products, for which sterility
is guaranteed by the manufacturing process, are industrially
manufactured all-in-one admixtures provided as multichamber
bags (MCBs). Compounding processes in hospital pharmacies
vary extensively from using manual methods to automated
compounding devices. Signiﬁcant advances in automated tech-
nology have led to a shift from manual compounding procedures,and most PN today in the United States is prepared using
automated techniques. The American Society of Health-System
Pharmacists estimated that in 2000 approximately 65% of US
hospitals used automated compounding devices for parenteral
admixtures in their daily practice [6]. Moreover, changing health
care pressures demand that admixture compounding be as safe
and efﬁcient as possible. The decision around PN choice can be
complex, and there are no speciﬁc guidelines advising the
appropriate circumstances under which premixed, standardized,
or custom PN should be used for various patient populations [6].
Several studies have evaluated the cost of different PN com-
pounding methods [7–9]. A few studies evaluated the cost of care
for patients on PN, but most evaluated only small, select pop-
ulations that are not easily generalizable to other patient pop-
ulations or hospitals. Of most recent, we analyzed the acquisition
costs associated with compounded PN versus premixed MCB PN
[10]. Clinical and economic outcomes were evaluated for hospi-
talized patients between January 2005 and December 2007.
Patients receiving compounded PN compared with those receiv-
ing premixed PN were at a higher risk for bloodstream infections
(odds ratio ¼ 1.56; 95% conﬁdence interval 1.37–1.79; P o 0.0001).Outcomes Research (ISPOR).
d to the study while at Baxter Healthcare.
-3W, One Baxter Parkway, Deerﬁeld, IL 60015.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 2 8 – 3 3 3 329Moreover, the acquisition cost of PN for premixed MCBs in
this study was lower than that of compounded PN (US $164 vs.
US $239). Although acquisition costs are important to hospitals as
they attempt to constrain the cost of care, the more relevant
parameter for researchers to investigate is total costs associated
with patients during hospitalization.
This analysis is an update to our previous analysis [11], using
a later time period for the catchment population and evaluation
of updated codes for infection identiﬁcation. The goal was to
compare two PN delivery techniques (premixed MCBs vs. com-
pounded PN) as it relates to total costs, length of stay (LOS),
infectious complications, and hospital readmission rates. This
retrospective study assesses a large number of critically ill adult
patients who received PN. The sample includes a large number of
hospitals from across the United States. The study tested the
hypothesis that patients receiving PN via MCBs have lower total
costs than do patients treated with compounded solutions (COM).
The clinical effectiveness of MCB versus COM was assessed
through the evaluation of a number of infection-related out-
comes, LOS, and hospital readmission rates.Methods
Data Source
Premier’s Hospital Database is the largest US hospital clinical and
economic database developed for quality and utilization bench-
marking. It contains a total of 2.5 billion patient daily service
records, and about 45 million records are added each month.
Annually, more than 5 million inpatient discharges and 35
million hospital outpatient visits are recorded in the database.
In addition to the data elements available in most of the standard
hospital discharge ﬁles, the Premier Hospital Database contains a
date-stamped log of all billed items including procedures, med-
ications, laboratory, and diagnostic and therapeutic services at
the individual patient level.
The Premier Hospital Database is a complete census of all
inpatients and hospital-based outpatients from more than 600
geographically diverse hospitals. It is not a random sample;
information on all patients treated from all therapeutic areas is
collected and retained in the database.
Data exist from calendar year 2000 forward. Patients can be
tracked across the inpatient and hospital outpatient settings, as
well as across visits with a unique person identiﬁer. All proce-
dures and diagnoses are captured for each patient, as well as all
drugs and devices received. There is no limit to any of the
aforementioned elements on the number recorded in the data-
base. Patients can be identiﬁed as to whether they were treated in
the intensive care unit (ICU) or ward bed by day of service on the
basis of the data from the hospital charge master. Drug utiliza-
tion information is available by day of stay and includes quantity,
dosing, strength used, and cost. Costs are as reported in hospital
charge masters and include room and board, pharmacy, labora-
tory, imaging, central supply, and all costs incurred by the
hospital including general and administrative (overhead). This
does not represent hospital charge or reimbursement.
The All Patient Reﬁned (APR) diagnosis-related group and APR
Severity Level are proprietary to 3M Health Information Systems.
This methodology assigns a severity of illness (minor, moderate,
severe, or extreme) on the basis of patient-speciﬁc information
and is used by several states for reimbursement purposes [11]. All
data within the Premier database are compliant with regulations
deﬁned in the 1996 Health Insurance Portability and Account-
ability Act and subsequent revisions. Data deliverables contain
limited Protected Health Information. Therefore, the time
of admission and discharge is provided as month and year.Day-of-service level details are reported using chronological days
(e.g., day 1, day 2). The age of patients older than 89 years is
reported as 89 years.
Patient Selection and Matching
The study population included all adult (ageZ 18 years) critically
ill inpatients who received PN, were in the ICU for 3 days or more,
and were discharged between January 1, 2010, and June 30, 2011.
Patients were then categorized as receiving MCB or COM. MCB PN
was deﬁned as patients receiving PN with a description including
Clinimix (manufactured PN in a dual-chamber bag with glucose
and amino acids, which may have included additions of miner-
als, vitamins, and/or electrolytes), whereas COM was identiﬁed as
PN with a description of Admix or Compound. These patients
constituted the primary study population.
Patients’ demographic characteristics and hospital character-
istics were identiﬁed for all patients. Speciﬁc comorbidities
(pancreatitis, liver impairment, renal failure, diabetes, malnutri-
tion, gastrointestinal disorders, and malabsorption) were identi-
ﬁed using International Classiﬁcaion of Diseases, Ninth Revision (ICD-9)
diagnosis codes (see Appendix A in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2014.02.009).
Patients were matched using a propensity score method with
a greedy match algorithm. Patients were matched to reduce any
selection bias and confounding of PN method indication [12]. The
propensity model included patients’ demographic variables (age,
race, sex, and admission type), patients’ clinical covariates (mal-
absorption, pancreatitis, liver impairment, renal failure, diabetes,
malnutrition, gastrointestinal disorder, number of days in ICU,
and ﬁrst day of parenteral feeding), and hospital characteristics
(geographic region, teaching status, and urban/rural status). The
likelihood-ratio test, Hosmer-Lemshow goodness of ﬁt, and con-
cordance c statistics (0.84) were utilized to assess the goodness of
ﬁt of the models.
Outcome Measures and Statistical Analyses
The primary outcomes for analysis included total hospitalization
costs (inclusive of inpatient stay, professional care, and medica-
tions), total LOS, and ICU LOS. Secondary outcomes of interest
were urogenital candidiasis, disseminated candidemia, blood-
stream infection, composite infection measure, any infection
complication, inpatient death, 30-day all-cause readmission, and
90-day all-cause readmission. For infection-related outcomes, a
patient was identiﬁed as possibly being infected if he or she had a
discharge ICD-9 code present for a speciﬁc infection (see Appendix
B in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2014.02.009). If patients, however, had a discharge ICD-9 code
of infection yet did not receive any antibiotic or antifungal during
their hospitalization, they were not considered infected; to be
considered infected, a patient had to have both a diagnosis of
infection and be treated with antimicrobial agents. Patients with
infection codes noted as present on admission (i.e., before the
institution of PN) were not evaluated because we were interested
in nosocomial infection cases that may be associated with PN.
Univariate descriptive statistics were calculated for all patient
and hospital covariates. Univariate analysis utilized chi-square
tests for categorical data and Student t tests or Wilcoxon sign
rank test for continuous variables.
Multivariate analysis of outcome measures utilized general-
ized linear models. LOS and cost outcomes were analyzed using
multivariate regression with a gamma distribution and a log link
due to the skewed nature of the data. Binary outcomes were
analyzed using multivariate logistic regression. The analysis
accounted for potential confounding factors by inclusion of
relevant clinical and demographic covariates. Final models were
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concordance c statistics, or scaled deviance as appropriate.
Separate analyses were performed on medical and surgical
patients (based on Medicare-severity-diagnosis-related group
classiﬁcation). No differences were found between these sub-
groups, and therefore all presentation of data will be on the entire
eligible population.Results
Patient Population
There were 65,415 patients who met the eligibility criteria (5,679
patients receiving MCB and 59,736 patients receiving COM). AfterTable 1 – Baseline demographic characteristics of patien
MCB
Discharges
Sample discharges 3559
Age (y)
18–44 301
45–64 1116
65–74 866
75–84 877
85þ 399
Sex
Female 1777
Male 1782
Discharge status
Expired 756
Home 1006
Other 0
Transferred to SNF, LTC, ICF, or acute 1797
APR-DRG severity of illness
1—Minor 11
2—Moderate 116
3—Major 657
4—Extreme 2775
Total 3559
First day parenteral feeding
Day 1 326
Day 2–4 1408
Day 5–9 1164
Day 10–19 546
Day 20þ 115
Length of parenteral feeding (d)
1 352
2–4 1227
5–9 1097
10–19 650
20þ 233
Comorbidities
Pancreatitis 308
Liver impairment 451
Renal failure 2062
Diabetes 1353
Malnutrition 979
Gastrointestinal disorders 1416
Malabsorption 69
APR, All Patient Reﬁned; COM, compounded solutions; DRG, diagnosis
facility; MCB, multichamber bag; SNF, skilled nursing facility.propensity matching, a total of 7,118 eligible subjects remained
(3,559 MCB and 3,559 COM). The ﬁnal propensity score model
produced a concordance c statistic of 0.81. Results of patient
demographic comparisons of matched populations are presented
in Table 1. The mean age for patients receiving MCB and COM
was similar (66.69 years MCB vs. 66.19 years COM; P ¼ 0.153).
There were signiﬁcant differences between groups in discharge
status because a higher percentage of patients receiving MCB
were transferred to a skilled nursing facility or long-term care
facility (50.49% MCB vs. 45.01% COM; Po 0.001). Patients receiving
MCB had higher rates of commercial or other as primary payer
and a greater percentage of patients receiving length of PN for 1
or 2 to 4 days compared with patients receiving COM. On the
basis of the inclusion criteria of 3 days or more in the ICU, the
patient acuity level was high as evidenced by 77% of both cohortsts receiving MCB and COM.
COM P
% Discharges %
3559
8.46 317 8.91
0.9340
31.36 1121 31.50
24.33 842 23.66
24.64 873 24.53
11.21 406 11.41
49.93 1752 49.23
0.553450.07 1807 50.77
21.24 749 21.05
o0.0001
28.27 1207 33.91
0.00 1 0.03
50.49 1602 45.01
0.31 10 0.28
0.9138
3.26 126 3.54
18.46 648 18.21
77.97 2775 77.97
3559
9.16 323 9.08
0.9805
39.56 1394 39.17
32.71 1184 33.27
15.34 549 15.43
3.23 109 3.06
9.89 305 8.57
0.0011
34.48 1118 31.41
30.82 1135 31.89
18.26 763 21.44
6.55 238 6.69
8.65 305 8.57 0.8991
12.67 465 13.07 0.6202
57.94 2071 58.19 0.8288
38.02 1300 36.53 0.1939
27.51 961 27.00 0.6318
39.79 1464 41.14 0.2464
1.94 75 2.11 0.6135
-related group; ICF, intermediate care facility; LTC, long-term care
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approximately two-thirds of the eligible population having an
APR risk of mortality as extreme. Comorbidities were similar
between groups (Table 1).
Hospital Characteristics
There were 145 hospitals included in the MCB group and 212 in
the COM group. There were no signiﬁcant differences in region
because it was a covariate in the propensity score model.
Signiﬁcant differences were found in urban-rural status and bed
size (Table 2), with the MCB group having higher rates of rural
and smaller bed size than did the COM cohort.
Unadjusted Analysis
The unadjusted total costs were signiﬁcantly 9.4% lower for
patients receiving MCB ($54,448 for MCB vs. $60,081 for COM;
P o 0.001). There was also a signiﬁcant difference in total LOS
(19.74 days for MCB vs. 20.54 days for COM; P o 0.001); however,
ICU LOS showed no signiﬁcant difference between groups (10.77
days for MCB vs. 10.63 days for COM; P ¼ 0.609). Readmission to the
hospital at 90 days was signiﬁcantly lower in the MCB versus COM
groups (25.3% for MCB vs. 28.8% for COM; P ¼ 0.006). There were no
signiﬁcant differences in unadjusted rates of the secondary out-
comes of infections, death, or readmission at 30 days (Table 3).
Multivariate Analysis
After adjusting for patient factors (age, sex, race, admission
source, admission type, physician specialty, and length of treat-
ment) including comorbidities (see Appendix A in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.02.009) andTable 2 – Hospital characteristics of patients receiving M
MCB
Hospitals %
Number of premier hospitals 145
Discharges %
Sample discharges 3559
Provider region
East North Central 558 15.6
East South Central 152 4.2
Middle Atlantic 234 6.5
Mountain 57 1.6
New England 11 0.3
Paciﬁc 434 12.1
South Atlantic 995 27.9
West North Central 385 10.8
West South Central 733 20.6
Population served
Rural 762 21.4
Urban 2797 78.5
Teaching status
Nonteaching 2728 76.6
Teaching 831 23.3
Hospital bed size
006–099 152 4.2
100–199 702 19.7
200–299 783 22.0
300–499 1280 35.9
500þ 642 18.0
COM, compounded solutions; MCB, multichamber bag.hospital characteristics (region, teaching status, urban/rural sta-
tus, and bed size), total costs for patients receiving MCB were
9.1% lower than for patients receiving COM ($37,790 for MCB vs.
$41,569 COM; P o 0.001). Figure 1 depicts total hospital-reported
costs for the unadjusted and adjusted analysis. Total hospital
LOS for patients receiving MCB was slightly shorter at 2.6% (9.40
days for MCB vs. 9.65 days for COM; P ¼ 0.014). Readmission at 90
days was also signiﬁcantly lower for the MCB group (odds ratio ¼
0.845; P ¼ 0.01). There was no signiﬁcant difference for length of
ICU stay between groups (4.02 days for MCB vs. 4.03 days for COM;
P ¼ 0.789). In addition, there were no signiﬁcant differ-
ences between groups for infections, death, and 30-day
readmission rates.Discussion
This study sought to provide a more comprehensive economic
analysis than previous studies evaluating total cost incurred by
hospitalized patients receiving PN via premixed MCB or com-
pounded PN solutions. There were signiﬁcantly lower total costs
when comparing MCB with COM. Infections, however, were not
signiﬁcantly different between groups in this analysis. Total costs
are driven by product purchasing and treatment costs associated
with underlying diseases and complications during hospitaliza-
tion. We found a signiﬁcant difference in total LOS between
patient groups. The difference, however, is small, and additional
studies are recommended to investigate parameters that may
explain the differences in total costs between groups.
Our ﬁndings are consistent with previous studies evaluating
comparable patient populations. Reductions in infections rates
were also observed in an analysis by Pontes-Arruda et al. [13],CB and COM.
COM P
Hospitals %
212
Discharges %
3559
8 553 15.54 0.8006
7 179 5.03
7 228 6.41
0 58 1.63
1 8 0.22
9 437 12.28
6 1,028 28.88
2 375 10.54
0 693 19.47
1 672 18.88 0.0078
9 2887 81.12
5 2763 77.63 0.3232
5 796 22.37
7 156 4.38 o.0001
2 327 9.19
0 891 25.04
7 1451 40.77
4 734 20.62
Table 3 – Unadjusted analysis, clinical and economic outcomes for patients receiving MCB and COM.
MCB (n ¼ 3,559) COM (n ¼ 3,559) P
Continuous variables, mean  SD
Total costs* 54,448  52,004 60,081  52,933 o0.001
Length of stay* 19.74  15.57 20.54  15.44 0.041
Total ICU days 10.77 11.02 10.63  10.30 0.609
Dichotomous variables, n (%)
Infection complications 1,224 (34.4) 1,214 (34.1) 0.803
Urogenital candidiasis 72 (2.0) 82 (2.3) 0.415
Disseminated candidemia 34 (1.0) 37 (1.0) 0.721
Bloodstream infection 60 (1.7) 73 (2.1) 0.255
Proxy measure 779 (21.9) 824 (23.2) 0.202
Death 756 (21.2) 749 (21.1) 0.839
30-d readmission 393 (16.4) 444 (17.8) 0.196
90-d readmission 608 (25.3) 720 (28.8) 0.006
COM, compounded solutions; ICU, intensive care unit; LOS, length of stay; MCB, multichamber bag.
* LOS and cost data were analyzed using multivariate regression and log transformed because of the skewed nature of the data.
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PN versus MCB PN (29.6 vs. 24.9%; odds ratio ¼ 1.29; 95% conﬁdence
interval ¼ 1.06–1.59) [13]. Using Premier inpatient database, Turpin
et al. [14] found that adult patients who received MCB had signiﬁ-
cantly lower risk of bloodstream infections than did those who
received pharmacy-prepared PN (19.6% vs. 25.9%; P o 0.001).
Economically, this study also reports that patients receiving MCB
incurred lower PN acquisition costs than did the COM group. In a
randomized trial, Pichard et al. [7] conducted a detailed cost
comparison of PN methods inclusive of single bottles, hospital
compounded bags, and MCBs. Costs were calculated including
manpower, nutrient solutions, and medical supplies. MCBs were
signiﬁcantly the least expensive method for providing PN where
application costs of single bottles and hospital compounded bags
were 120% and 150% of multichamber costs, respectively. Moreover,
the study reports a daily saving of 50% with MCBs over hospital-
compounded bag. Genton et al. [8] discuss that the use of MCBs is a
cost-saving strategy in European and North American countries
where manpower usually represents 85% of hospital costs.
Guidelines from the European Society for Clinical Nutrition
and Metabolism recommend that PN be initiated within 24 to 48
hours in ICU patients who are not expected to return to normal
intake for 3 days and have a contraindication to enteral nutri-
tion (EN). Joint guidelines from the American Society forFig. 1 – Total hospital-reported costs. COM, compParenteral and Enteral Nutrition and the Society for Critical
Care Medicine advocate waiting until 7 days after admission to
the ICU before providing PN when EN is not feasible [15,16]. In
this study of critically ill patients, PN was initiated in approx-
imately 9% of the patients on day 1, 39% of the patients between
days 2 and 4, and 31% of the patients between days 5 and 9.
Thus, approximately, 80% of the patients received PN by day 9.
The results are more reﬂective of the European Society for
Clinical Nutrition and Metabolism guidelines. It must be noted,
however, that many patients may have received PN earlier than
day 7 as a result of intolerance of EN.
The ﬁndings from this study should be considered in light of
limitations. Patients receiving MCB and COM were matched
using propensity scores, but the scores may not have accounted
for baseline disease severity between the groups. In addition,
although the analysis controlled for hospital region, bed size,
and teaching status, we did not control for the potential impact
of site-site differences on outcomes. The method of compound-
ing (whether automated or manual) was not identiﬁed in this
study. Automated compounding is associated with improved
patient safety, enhanced efﬁciency, and reduced costs compared
with manual compounding. Moreover, the Centers for Medicare
& Medicaid Services implemented changes to the hospital
Inpatient Prospective Payment Systems in 2008 and under thoseounded solutions; MCB, multichamber bag.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 2 8 – 3 3 3 333reforms treatment of certain types of conditions, including vascu-
lar catheter-associated infections acquired during a hospital stay,
may not qualify for reimbursement [17]. This policy of not paying
hospitals for preventable complications is intended to remove the
incentive of receiving greater reimbursements for care provided for
preventable conditions [18]. It remains unclear whether these
incentives have changed hospital coding practice or whether the
new catheter-infection codes accurately identify events and future
studies should investigate potential impact [19,20].
Further limitations result from the inclusion criteria of iden-
tifying patients as having an infection if they had a discharge ICD-
9 code of infection and received antibiotic or antifungal treatment
during their hospitalization. A conservative criterion was applied
assuming that if patients had an infection then most likely they
would be administered antibiotic or antifungal medications. The
results from this study regarding infections differ from previous
results obtained by Turpin et al. [14] The reasons for the differ-
ences between studies may relate to differences in patient
populations, differences in coding of infections, differences in
severity of illness, differences in preparation techniques, differ-
ences in care of intravenous catheters, catchment population, and
many other factors. Moreover, we found a signiﬁcant difference
between groups for 90-day readmission rates. The difference may
reﬂect differences in underlying disease severity between groups
that was not accounted for in the analyses. In addition, details of
PN additions (vitamins, minerals, electrolytes, lipids, etc.) and
preparation sites were not identiﬁed in the current study. Thus,
results from this study may not be generalizable to three-chamber
premixed formulations containing lipid emulsions and may not
be generalizable to all compounded PN formulations.
In summary, we compared the administration of PN using two
different techniques, a premixed MCB and a compounded PN
formulation. In this retrospective analysis that matched patients
in each group for various parameters, we found lower total costs,
lower hospital LOS, and lower 90-day readmission rates in the MCB
versus COM group. Infectious complications, death, and 30-day
readmission rates were similar between groups. The differences
between groups allow for the generation of new hypotheses that
should be tested in prospective randomized studies. We hope that
these supportive results along with related published literature
will heighten awareness around risk factors for infections, partic-
ularly associated with the use of PN. With this information, health
care providers should focus on best practices to reduce blood-
stream infection risk and to improve patient outcomes as well as
reduce the overall economic burden to the health care system.
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